title: DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.
abstract: OBJECTIVE
  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts.
  
  
  METHODS
  Groups 1-4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining.
  
  
  RESULTS
  DCE-MRI measured a significant K (trans) change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K (trans) changes followed quadratic polynomial curves.
  
  
  CONCLUSIONS
  DCE-MRI detected significantly lower K (trans) levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
authors.affiliation: The Department of Radiology, University of Alabama at Birmingham, AL 35294, USA. Hyunki@uab.edu
authors.forename: Hyunki
authors.initials: H
authors.lastname: Kim
authors.forename: Karri D
authors.initials: KD
authors.lastname: Folks
authors.forename: Lingling
authors.initials: L
authors.lastname: Guo
authors.forename: Cecil R
authors.initials: CR
authors.lastname: Stockard
authors.forename: Naomi S
authors.initials: NS
authors.lastname: Fineberg
authors.forename: William E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: James F
authors.initials: JF
authors.lastname: George
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Buchsbaum
authors.forename: Desiree E
authors.initials: DE
authors.lastname: Morgan
authors.forename: Kurt R
authors.initials: KR
authors.lastname: Zinn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008819:Mice, Nude; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology*; D014183:Transplantation, Heterologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D000068258:Bevacizumab
references.citation: J Biol Chem. 1998 Jun 5;273(23):14363-7
references.pmid: 9603945
references.citation: Nat Med. 2001 Aug;7(8):954-60
references.pmid: 11479629
references.citation: Neoplasia. 2000 Jan-Apr;2(1-2):152-65
references.pmid: 10933074
references.citation: Child Dev. 1985 Aug;56(4):787-809
references.pmid: 4042744
references.citation: Magn Reson Med. 2007 Aug;58(2):270-80
references.pmid: 17654590
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Kidney Int. 2007 Aug;72(3):260-4
references.pmid: 17507905
references.citation: Nat Med. 2000 May;6(5):564-7
references.pmid: 10802713
references.citation: Magn Reson Imaging. 2005 May;23(4):519-29
references.pmid: 15919597
references.citation: J Clin Oncol. 2006 Feb 10;24(5):769-77
references.pmid: 16391297
references.citation: J Transl Med. 2005 May 19;3(1):22
references.pmid: 15943879
references.citation: J Magn Reson Imaging. 2004 Jan;19(1):68-75
references.pmid: 14696222
references.citation: Invest Radiol. 1992 Aug;27 Suppl 1:S12-5
references.pmid: 1506147
references.citation: Science. 1997 Aug 8;277(5327):818-21
references.pmid: 9242611
references.citation: J Ultrasound Med. 2007 Jun;26(6):749-56
references.pmid: 17526606
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5464-73
references.pmid: 16027440
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41
references.pmid: 14506165
references.citation: Breast Cancer Res Treat. 2003 Mar;78(1):51-8
references.pmid: 12611457
references.citation: Mol Cancer Ther. 2007 Mar;6(3):866-75
references.pmid: 17363481
references.citation: Magn Reson Med. 2004 Mar;51(3):542-51
references.pmid: 15004796
references.citation: Radiology. 2008 Sep;248(3):844-51
references.pmid: 18710978
references.citation: Magn Reson Imaging. 2007 Apr;25(3):319-27
references.pmid: 17371720
references.citation: J Neurol Sci. 2007 Aug 15;259(1-2):53-60
references.pmid: 17395209
references.citation: Magn Reson Med. 2007 Feb;57(2):353-61
references.pmid: 17260371
references.citation: Radiology. 2002 May;223(2):319-25; discussion 326-7
references.pmid: 11997531
references.citation: Technol Cancer Res Treat. 2006 Aug;5(4):401-10
references.pmid: 16866570
references.citation: Cancer Lett. 2003 Nov 10;201(1):17-24
references.pmid: 14580682
references.citation: Cancer Biother Radiopharm. 2010 Feb;25(1):13-9
references.pmid: 20187792
references.citation: Neoplasia. 2004 May-Jun;6(3):213-23
references.pmid: 15153333
references.citation: Breast Cancer Res Treat. 2004 Jan;83(1):67-76
references.pmid: 14997056
references.citation: Eur J Cancer. 2004 Apr;40(6):802-20
references.pmid: 15120036
references.citation: Magn Reson Med. 2002 Jun;47(6):1110-20
references.pmid: 12111957
references.citation: J Magn Reson Imaging. 1999 Sep;10(3):223-32
references.pmid: 10508281
references.citation: Nihon Rinsho. 2007 Jun 28;65 Suppl 6:385-8
references.pmid: 17679210